Enliven Therapeutics, Inc. (ELVN)
46.97
+0.76
(+1.64%)
USD |
NASDAQ |
Oct 02, 16:00
46.97
0.00 (0.00%)
After-Hours: 20:00
Enliven Therapeutics Net Income (Quarterly) : -32.48M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -32.48M |
| March 31, 2026 | -23.63M |
| December 31, 2025 | -29.67M |
| September 30, 2025 | -20.15M |
| June 30, 2025 | -25.34M |
| March 31, 2025 | -28.54M |
| December 31, 2024 | -23.18M |
| September 30, 2024 | -23.16M |
| June 30, 2024 | -19.95M |
| March 31, 2024 | -22.74M |
| December 31, 2023 | -19.37M |
| September 30, 2023 | -20.77M |
| June 30, 2023 | -16.72M |
| March 31, 2023 | -14.72M |
| Date | Value |
|---|---|
| December 31, 2022 | 32.18M |
| September 30, 2022 | -10.55M |
| June 30, 2022 | -8.889M |
| March 31, 2022 | -8.669M |
| December 31, 2021 | -14.32M |
| September 30, 2021 | -13.65M |
| June 30, 2021 | -13.16M |
| March 31, 2021 | -10.26M |
| December 31, 2020 | -11.52M |
| September 30, 2020 | -12.42M |
| June 30, 2020 | -10.20M |
| March 31, 2020 | -7.215M |
| December 31, 2019 | -7.25M |
| September 30, 2019 | -6.622M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Definium Therapeutics, Inc. | -158.99M |
| Cocrystal Pharma, Inc. | -3.164M |
| CNBX Pharmaceuticals, Inc. | -0.1542M |
| Arvinas, Inc. | 169.40M |
| Fulcrum Therapeutics, Inc. | -26.18M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 32.48M |
| EPS Diluted (Quarterly) | -0.4909 |
| Enterprise Value | 2.547B |
| Earnings Yield | -3.55% |
| Normalized Earnings Yield | -3.552 |